the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
June 16, 2017 – Patient education in pharmacogenetics, the central component of theragenomic and personalized medicine and individualized drug safety is an important issue. Not only needs the individual patient to understand what pharmacogenetics, or more precisely, pharmacogenetic testing can …
Development of a patient education video about pharmacogenetics Read more »
Through a new boxed warning, the FDA is alerting healthcare professionals about a subgroup of patients who cannot effectively metabolize the anti-platelet drug Clopidogrel [Plavix]. These patients, called “poor metabolizers,” have little or no activity of the liver enzyme CYP2C19, …
Reduced Effect from Clopidogrel [Plavix] in “Poor Metabolizer” Patients Read more »
March 21, 2010 – Doctors are reporting an exciting win for gene testing and personalized medicine: Checking patients’ DNA before starting them on a popular blood thinner helps get the tricky dose right and keep them out of the hospital. …
Gene Testing Helps Get Warfarin [Coumadin] Dose Right Read more »
March 17, 2010 – The U.S. Food and Drug Administration (FDA) has added a Boxed Warning to the label for Clopidogrel [Plavix], the anti-blood clotting medication. The Boxed Warning is about patients who do not effectively metabolize the drug (i.e. …